Generic Name and Formulations:
Lipase/protease/amylase; 4000Units/8000Units/8000Units, 13800Units/27600Units/27600Units, 20700Units/41400Units/41400Units, 23000Units/46000Units/46000Units; del-rel caps; e-c minitabs in caps.
Indications for ULTRESA:
Treatment of exocrine pancreatic insufficiency due to cystic fibrosis, or other conditions.
Adults and Children:
Start at the lowest recommended dose and increase gradually. Individualize based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet. Swallow whole; do not crush or chew caps. May mix contents with applesauce or other acidic soft food (pH≤ 4.5); swallow mixture immediately, follow with water or juice; take with meals; do not let any drug remain in mouth. ≤12mos: 4000 lipase units per 120mL of formula or per breastfeeding; give prior to each feeding, do not mix directly. >12mos–<4yrs: initially 1000 lipase units/kg per meal. ≥4yrs: initially 500 lipase units/kg per meal. Max (>12mos): 2500 lipase units/kg per meal (or ≤10000 lipase units/kg/day), or <4000 lipase units/g fat ingested/day. See full labeling.
Not interchangeable with other pancrelipase products. Fibrosing colonopathy (with high doses); risk of stricture formation (monitor). Pork allergy. Potential viral transmission. Gout. Renal impairment. Hyperuricemia. Contents irritating to oral mucosa. Pregnancy (Cat.C). Nursing mothers.
Pancreatic enzymes (porcine).
Headache, pharyngolaryngeal pain, epistaxis; allergic reactions.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Undifferentiated Headaches Common in Children, Adolescents
- Smoking Associated With Increased Relapse Rate in Interferon Beta-Treated Relapsing-Remitting MS
- Frontotemporal Dementia, Frontotemporal Lobar Degeneration Symptoms More Common Later in Life
- No Reduction in Cerebral Perfusion With Intensive Blood Pressure Lowering
- Successful Delirium Prevention in Critically Ill With Dexmedetomidine